Faron Pharmaceuticals Oy (LON:FARN – Get Free Report)’s stock price hit a new 52-week low during mid-day trading on Thursday. The company traded as low as GBX 32 and last traded at GBX 32.50, with a volume of 27,079 shares trading hands. The stock had previously closed at GBX 36.
Faron Pharmaceuticals Oy Trading Down 9.7%
The stock has a market capitalization of £65.94 million, a PE ratio of -2.82 and a beta of 1.12. The company has a current ratio of 2.40, a quick ratio of 1.09 and a debt-to-equity ratio of 154.15. The firm has a 50-day moving average price of GBX 37.04 and a 200-day moving average price of GBX 40.85.
Faron Pharmaceuticals Oy Company Profile
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
Further Reading
- Five stocks we like better than Faron Pharmaceuticals Oy
- Is Texas Instruments Setting Up for Its Next Big Breakout?
- Pegasystems’ Q3 Miss Exposed the Problem Standing Between AI and Cash Flow
- Lam Research’s Earnings Beat Wasn’t the Real Story—Its 2027 Outlook Was
- Tesla’s Flying-Car Hype Hits an Earnings Reality Check
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.
